Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19
暂无分享,去创建一个
Amrita X. Sarkar | E. Wherry | L. Rauova | A. Greenplate | D. Oldridge | S. Hensley | D. Dunbar | I. Frank | M. Poncz | A. Baxter | J. Giles | N. Meyer | S. Gouma | C. Abrams | J. Reilly | S. Manne | Zeyu Chen | A. Huang | L. Vella | C. Alanio | H. Giannini | Jennifer E. Wu | C. Ittner | D. Mathew | Josephine R. Giles | Yinghui Jane Huang | Sokratis A. Apostolidis | Mohamed S. Abdel-Hakeem | A. Pattekar | S. Apostolidis | A. Weisman | O. Kuthuru | J. Dougherty | R. Goel | Liang Zhao | Aae Suzuki | Brittany Weiderhold | Y. J. Huang | Zeyu Chen
[1] A. Iwasaki,et al. The first 12 months of COVID-19: a timeline of immunological insights , 2021, Nature reviews. Immunology.
[2] D. Rader,et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection , 2021, Cell.
[3] J. Kelton,et al. Platelet Activating Immune Complexes Identified in COVID-19 Associated Coagulopathy , 2020, medRxiv.
[4] I. Tleyjeh,et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis , 2020, Clinical Microbiology and Infection.
[5] C. Viboud,et al. Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China , 2020, Nature Communications.
[6] Yang Han,et al. Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19 , 2020, Immunity.
[7] P. Sorger,et al. Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques , 2020, Cell.
[8] Karl Erik Müller,et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients , 2020, Proceedings of the National Academy of Sciences.
[9] C. Wellington,et al. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome , 2020, European Respiratory Journal.
[10] Hyun Kang,et al. The Potential Role of Dyslipidemia in COVID-19 Severity: an Umbrella Review of Systematic Reviews , 2020, Journal of lipid and atherosclerosis.
[11] M. Shankar-Hari,et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study , 2020, The Lancet Respiratory Medicine.
[12] L. Ware. Physiological and biological heterogeneity in COVID-19-associated acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.
[13] Arthur S Slutsky,et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study , 2020, The Lancet Respiratory Medicine.
[14] J. Ravetch,et al. The role of IgG Fc receptors in antibody-dependent enhancement , 2020, Nature Reviews Immunology.
[15] Jessica K De Freitas,et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection , 2020, Nature Medicine.
[16] F. Vély,et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis , 2020, Nature.
[17] C. Righy,et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 , 2020, Blood.
[18] Robert A. Campbell,et al. Platelet gene expression and function in patients with COVID-19 , 2020, Blood.
[19] J. Atkinson,et al. The complement system in COVID-19: friend and foe? , 2020, JCI insight.
[20] John D Lambris,et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis , 2020, medRxiv.
[21] A. Zangrillo,et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study , 2020, European Journal of Internal Medicine.
[22] Shenmin Zhang,et al. Proinflammatory IgG Fc structures in patients with severe COVID-19 , 2020, Nature Immunology.
[23] D. Gommers,et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.
[24] Norbert Stefan,et al. Obesity and impaired metabolic health in patients with COVID-19 , 2020, Nature Reviews Endocrinology.
[25] Yuan Yu,et al. Thrombocytopenia and its association with mortality in patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[26] Kaijun Jiang,et al. SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup , 2020, Current protocols in microbiology.
[27] Mario Plebani,et al. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis , 2020, Clinica Chimica Acta.
[28] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[29] L. Rauova,et al. Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contribute to thrombus propagation. , 2020, Blood.
[30] Dengju Li,et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.
[31] Eculizumab , 2020, Reactions Weekly.
[32] A. Tefferi,et al. Essential Thrombocythemia. , 2019, The New England journal of medicine.
[33] M. Rondina,et al. The Era of Thromboinflammation: Platelets Are Dynamic Sensors and Effector Cells During Infectious Diseases , 2019, Front. Immunol..
[34] H. Langer,et al. Platelets and Immune Responses During Thromboinflammation , 2019, Front. Immunol..
[35] B. Nilsson,et al. The Human Platelet as an Innate Immune Cell: Interactions Between Activated Platelets and the Complement System , 2019, Front. Immunol..
[36] S. Laradi,et al. Platelet Inflammatory Response to Stress , 2019, Front. Immunol..
[37] Stefano Spolitu,et al. Proprotein convertase subtilisin/kexin type 9 and lipid metabolism , 2019, Current opinion in lipidology.
[38] Peter J. Hogarth,et al. The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease , 2019, Front. Immunol..
[39] P. Gresele,et al. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention , 2019, Thrombosis and Haemostasis.
[40] J. Heemskerk,et al. Platelet biology and functions: new concepts and clinical perspectives , 2018, Nature Reviews Cardiology.
[41] Jiří Mayer,et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials , 2018, American journal of hematology.
[42] K. Ray,et al. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? , 2017, Heart.
[43] C. Fjell,et al. Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis , 2016, Journal of Innate Immunity.
[44] M. Gawaz,et al. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. , 2015, Atherosclerosis.
[45] Gustavo Leon,et al. Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study , 2014, Arthritis & rheumatology.
[46] C. Shaw,et al. Racial Difference in Human Platelet PAR4 Reactivity Reflects Expression of PCTP and miR-376c , 2013, Nature Medicine.
[47] T. Perez-Sanz,et al. Fatty Acid Binding Proteins and Cardiovascular Risk , 2013, Current Cardiovascular Risk Reports.
[48] H. Dauerman,et al. Platelet functions beyond hemostasis , 2009, Journal of thrombosis and haemostasis : JTH.
[49] C. Pirola,et al. Normal platelets possess the soluble form of IL-6 receptor. , 2004, Cytokine.
[50] J. Weissenbach,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.
[51] L. Brass,et al. Signaling through G Proteins in Platelets: to the Integrins and Beyond , 1997, Thrombosis and Haemostasis.